Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Starpharma, AstraZeneca deal

    Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer, Drug delivery AstraZeneca received rights to use Starpharma's DEP dendrimer drug …

    Published on 4/14/2014
  • Strox Biopharmaceuticals, Xbiotech deal

    Strox Biopharmaceuticals LLC, Wellington, Fla. XBiotech Inc., Austin, Texas Business: Infectious XBiotech acquired Strox's patent estate for an undisclosed antibody therapy for methicillin-resistant Staphylococcus …

    Published on 4/14/2014
  • Tetra Discovery, Broad Institute of MIT and Harvard deal

    Tetra Discovery Partners LLC, Grand Rapids, Mich. Broad Institute of MIT and Harvard, Cambridge, Mass. Business: Neurology Tetra partnered with the institute's Stanley Center for Psychiatric Diseases to evaluate the …

    Published on 4/14/2014
  • Singulex, Tecan deal

    Singulex Inc., Alameda, Calif. Tecan AG (SIX:TECN), Mannedorf, Switzerland Business: Diagnostic The companies will co-develop the Sgx Clarity ultrasensitive immunoassay system for in vitro diagnostics. The system will …

    Published on 3/31/2014
  • SQI Diagnostics deal

    SQI Diagnostics Inc. (TSX-V:SQD), Toronto, Ontario Business: Pharmaceuticals SQI expanded its deal to develop a custom multiplex test for a drug from an undisclosed pharma. Under the expansion, SQI will develop a 21-…

    Published on 3/31/2014
  • TapImmune, Mayo Clinic deal

    TapImmune Inc. (OTCBB:TPIV), Seattle, Wash. Mayo Clinic, Rochester, Minn. Business: Cancer TapImmune signed an exclusive option agreement with Mayo for peptide epitopes targeting folate receptor 1 (FOLR1; FR-alpha) in …

    Published on 3/31/2014
  • Upsher-Smith, Vertical Pharmaceuticals deal

    Upsher-Smith Laboratories Inc., Maple Grove, Minn. Vertical Pharmaceuticals LLC, Sayreville, N.J. Business: Endocrine/Metabolic Vertical acquired Upsher-Smith's rights to Divigel estradiol gel, probiotic supplement …

    Published on 3/31/2014
  • Vectura deal

    Vectura Group plc (LSE:VEC), Chippenham, U.K. Business: Inflammation, Pulmonary, Drug delivery Vectura will receive a $3 million milestone payment from the U.S. division of an undisclosed pharma under a 2011 deal …

    Published on 3/31/2014
  • Acorda, NeurogesX deal

    Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. NeurogesX Inc. (OTCBB:NGSX), San Mateo, Calif. Business: Neurology Acorda acquired development and commercialization rights in territories that Astellas Pharma Inc.…

    Published on 7/15/2013
  • ADC Therapeutics, BioAtla deal

    ADC Therapeutics S.a.r.l., Lausanne, Switzerland BioAtla LLC, San Diego, Calif. Business: Cancer BioAtla's VivaMab therapeutic development division granted ADC Therapeutics rights to VivaMab's VM101 for hematologic …

    Published on 7/15/2013
  • Advancell, Helsinn deal

    Advancell Advanced In Vitro Cell Technologies S.A., Barcelona, Spain Helsinn Healthcare S.A., Pazzallo-Lugano, Switzerland Business: Dermatology Advancell granted Helsinn exclusive, worldwide rights to develop and …

    Published on 7/15/2013
  • Ahn-Gook, Gravity Bio Inc. deal

    Ahn-Gook Pharmaceutical Co. Ltd. (KOSDAQ:001540), Seoul, South Korea Gravity Bio Inc., Chapel Hill, N.C. Business: Pulmonary Gravity Bio said it received exclusive rights from Ahn-Gook to develop and commercialize cough…

    Published on 7/15/2013
  • Amgen, Onyx deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif. Business: Cancer Cancer company Onyx said its board rejected an unsolicited offer from Amgen, but said…

    Published on 7/15/2013
  • Amgen, Servier deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Servier, Neuilly-sur-Seine, France Business: Cardiovascular Servier granted Amgen U.S. commercialization rights to Servier's cardiovascular drug Procoralan ivabradine. The…

    Published on 7/15/2013
  • Arch Therapeutics deal

    Arch Therapeutics Inc. (OTCQB:ARTH), Cambridge, Mass. Business: Hematology Arch Therapeutics (formerly Almah Inc.) reverse-merged with Arch Biosurgery Inc., with Arch Therapeutics remaining as the surviving entity. The …

    Published on 7/15/2013
  • AriBio, SK Biopharmaceuticals deal

    AriBio, Seoul, South Korea SK Biopharmaceuticals Co. Ltd., Seoul, South Korea Business: Ophthalmic The companies partnered to conduct preclinical and clinical development of SK Biopharmaceuticals' SKL-G to treat …

    Published on 7/15/2013
  • Array BioPharma, Loxo deal

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Loxo Oncology Inc., New York, N.Y. Business: Cancer Array granted newco Loxo exclusive, worldwide rights to develop and commercialize undisclosed cancer candidates and …

    Published on 7/15/2013
  • Ascend Biopharmaceuticals, Transgene deal

    Ascend Biopharmaceuticals Ltd., Melbourne, Australia Transgene S.A. (Euronext:TNG), Illkirch, France Business: Cancer Transgene granted Ascend rights to develop and commercialize TG1042 (ASN-002) to treat basal cell …

    Published on 7/15/2013
  • Aspen, Merck deal

    Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Pharmaceuticals Aspen will acquire from Merck a Dutch API manufacturing plant in a deal that…

    Published on 7/15/2013
  • AstraZeneca, Karolinska Institute deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Karolinska Institute, Stockholm, Sweden Business: Cardiovascular, Endocrine/Metabolic AstraZeneca and the institute named the research center jointly created earlier …

    Published on 7/15/2013
  • AstraZeneca, Sarah Cannon Research Institute deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Sarah Cannon Research Institute, Nashville, Tenn. Business: Pharmacogenetics AstraZeneca and the institute partnered to predict responses to cancer therapies using …

    Published on 7/15/2013
  • Avanir, OptiNose deal

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. OptiNose Inc., Yardley, Pa. Business: Drug delivery, Neurology OptiNose granted Avanir exclusive North American rights to develop and commercialize its …

    Published on 7/15/2013
  • Base4 Innovation, Hitachi High-Technologies deal

    Base4 Innovation Ltd., Cambridge, U.K. Hitachi High-Technologies Corp. (Tokyo:8036), Tokyo, Japan Business: Genomics DNA sequencing company Base4 and medical systems manufacturer Hitachi partnered to develop a long read…

    Published on 7/15/2013
  • Biohit, Anhui Wisdom-Win Investment Co. Ltd. deal

    Biohit Oyj (HSE:BIOBV), Helsinki, Finland Anhui Wisdom-Win Investment Co. Ltd., undisclosed location Business: Diagnostic Biohit and Anhui Wisdom-Win formed a JV, Biohit Biotech (Hefei) Co. Ltd. (Hefei, China), to …

    Published on 7/15/2013
  • BioInvent deal

    BioInvent International AB (SSE:BINV), Lund, Sweden Business: Antibodies BioInvent said it will receive an undisclosed milestone payment from an undisclosed partner. The payment is triggered by the partner's start of a …

    Published on 7/15/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993